drugset / Trial / NCT03240523

A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids

NCT03240523

Phase 3 Terminated 766 enrolled Bayer
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to describe the efficacy of vilaprisan in subjects with uterine fibroids compared to ulipristal. The secondary objective of this study is to evaluate the efficacy and safety of different treatment regimens of vilaprisan in subjects with uterine fibroids.

Timeline

Start
2017-07-31
Primary completion
2020-06-28
Completion
2021-10-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Vilaprisan Other / unclassified 2 mg Oral